MILFORD, Pa., Feb. 3, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink: MNZO), today announced positive results from the six month animal study of Lacto-Freedom™, the company's lactase producing probiotic. This successful testing brings Manzo Pharmaceuticals, and partner, Celprogen, Inc., one step closer to human clinical trials.
The 6-month study was conducted by Celprogen,Inc. using laboratory rats to test the new probiotic treatment. Lab rats are the ideal mammals to test because they are naturally lactose intolerant. After 6 months the rats given the treatment showed no negative side effects, even at very high doses. All doses from low to high concentration were very successful at colonizing the intestines and producing lactase, which enabled rats to digest lactose. In addition, the blood glucose levels of the rats was significantly higher after treatment, and for the full 6 months, demonstrating that the lactose in their diet was properly broken down into glucose and galactose. This effect lasted for a full six months after the administration of the probiotic was discontinued. This long lasting residual effect is unique and is far superior to any other lactose intolerance treatment option currently on the market. Since approximately 25% of the population in the United States is lactose intolerant Manzo Pharmaceuticals and Celprogen are both confident that there will be a huge demand for this product.
Manzo Pharmaceuticals, Inc. also welcomes Dean Franchino to the project. Mr. Franchino has experience in the production of nutritional and pharmaceutical grade products, quality control, FDA regulations, research and development of new products and extensive knowledge of medical equipment. This will prepare Manzo Pharmaceuticals for the next phase of business after human trials, which will be to manufacture, package, and distribute Lacto-Freedom™ globally.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose Intolerance, and a natural remedy for colic in babies. For more information follow the company on Twitter at @manzopharma, and visit www.manzopharma.com.
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
SOURCE Manzo Pharmaceuticals, Inc.